Recent advances in the HER2 targeted therapy of gastric cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Recent advances in molecular targeted therapies, including targeting human epidermal growth factor receptor 2 (HER2), had a major forward step in the therapy for gastric cancer patients. Application of HER2-targeted therapies, in particular trastuzumab in combination with chemotherapy in metastatic HER2-positive gastric cancers, resulted in improvements in response rates, time to progression and overall survival. Nevertheless, as with breast cancer, many patients with gastric cancer develop resistance to trastuzumab. Several promising therapies are currently being developed in combination with chemotherapy to increase the efficacy and overcome the cancer-resistance. Here we review the current overview of clinical application of agents targeting HER2 in gastric cancer. We also discuss the ongoing trials supporting the use of HER2-targeted agents combined with cytotoxic agents or other monoclonal antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298
Cited by
Engineering hybrid exosomes by membrane fusion with liposomes
Sato, Y. T., Umezaki, K., Sawada, S., Mukai, S.-A., Sasaki, Y., Harada, N., Shiku, H., & Akiyoshi, K. (2016) · Scientific Reports · doi:10.1038/srep21933 · Cited by 744
Biomarkers of gastric cancer: Current topics and future perspective
Matsuoka, T., & Yashiro, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i26.2818 · Cited by 476
Self-citationHER2 testing in gastric cancer: An update
Abrahao-Machado, L. F., & Scapulatempo-Neto, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4619 · Cited by 310
Xu, M., Feng, T., Liu, B., Qiu, F., Xu, Y., Zhao, Y., & Zheng, Y. (2021) · Theranostics · doi:10.7150/thno.62330 · Cited by 229
Wang, D., Li, W., Yin, L., Du, Y., Zhang, S., & Suo, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.11350 · Cited by 12
“Identification of cancer biomarkers has been a major research focus in recent decades, and biomarkers, such as human epidermal growth factor receptor 2 in breast and gastric cancer, KRAS in colon and lung cancer, and epidermal growth factor receptor in colon and lung cancer, are now commonly used in clinical diagnosis…”
Metadata
- Authors
- Matsuoka, T.
- Venue
- World Journal of Clinical Cases
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 3
- Issue
- 1
- Pages
- 42
- ISSN
- 2307-8960 (ISSN-L)
- OpenAlex
- W2333973238
- Cited by
- 52
- References
- 1
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in the HER2 targeted therapy of gastric cancer. https://app.cochat.ai/papers/10.12998/wjcc.v3.i1.42
- The paper
- Matsuoka, T. (2015). Recent advances in the HER2 targeted therapy of gastric cancer. World Journal of Clinical Cases. https://doi.org/10.12998/wjcc.v3.i1.42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.